Search
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalEndothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.
Veligrotug
go.drugbank.com/drugs/DB18976Approved[L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63798] Although its precise mechanism in thyroid eye disease has not been fully characterized, IGF-1R blockade reduces the proptosis and diplopia that define the condition.
Synonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human-Mus musculus monoclonal VRDN-001 γ1-chain), disulfide with human-Mus musculus monoclonal VRDN-001 κ-chain, dimerV1003
go.drugbank.com/drugs/DB05046ExperimentalV1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both
Amobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitAdverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Nefiracetam
go.drugbank.com/drugs/DB13082InvestigationalNefiracetam has been used in trials studying the treatment of Alzheimer's Disease.
Categories: Compounds used in a research, industrial, or household settingElesclomol
go.drugbank.com/drugs/DB05719InvestigationalIt is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.
XL844
go.drugbank.com/drugs/DB05149InvestigationalXL844 is investigated for the use and treatment solid tumors. XL844 is a solid. … XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551].
Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-Carboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylateInterferon Gamma
go.drugbank.com/drugs/DB15753InvestigationalInterferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. … The interferon is primarily produced by activated T lymphocytes and natural killer cells.